According to research data specialists, 79% of their time is spent finding and organising data. The FAIR (Findable, Accessible, Interoperable, Reusable) data guiding principles were created to save researchers time and help to maximise the impact of health data.
Practical implementation of these principles, however, is easier said than done. Join us for our virtual series: Driving FAIR in Biopharma and hear the lessons learned from implementation and benchmark how you can improve FAIRification programmes in your organisation.
In this 3-part series we’re joined by FAIR champions implementing these principles to better govern data across the R&D value chain, starting on Tuesday 21st July at 4 pm BST/5 pm CET/11 am EST.
*** By signing up to this webinar, you are signing up to the series and will receive an automated email granting access to all subsequent webinars (approximately one week before each webinar).
Webinars:
21st July: How FAIR Champions Enable Change Management
During this virtual discussion we’ll look at who the senior stakeholders are involved in driving change management, and how companies can achieve “intent to insight” across all their data. Join us to understand the concerted efforts that are required for companies to transform their data into a strategic asset.
- Tom Plasterer, Director of Bioinformatics, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca
- Martin Romacker, Principal Scientist, Roche
- Andrea Splendiani, Director of Data Strategy, Novartis
- Philippe Rocca-Serra, Group Coordinator and Associate Member of Faculty, University of Oxford e-Research Centre
- Hans Constandt, President and Founder, ONTOFORCE
28th July: Off-the-Beaten-Track Use Cases of FAIR Implementation in Life Sciences
In this session, we will look into how drug discovery related data flows from CROs to pharma to regulatory agencies. We will discuss how the data flow is affected by FAIR data and its applications.
- Dr. Ellen L. Berg, Chief Scientific Officer, Translational Biology, Eurofins Discovery
- Dr. Lawrence Callahan, Chemist, Office of Health Informatics, Global Substance Registration System/Office of Health Informatics, Office of Chief Scientist, FDA
- Dr. Isabella Feierberg, Associate Principal Scientist, AstraZeneca
- Dr. Hande Küçük McGinty, Research Scientist, Collaborative Drug Discovery (CDD Inc.)
4th August: Enterprise-Wide Data Management Considerations
In this final session we’re joined by pharma leaders looking at how FAIR implementation affects broader IT and semantic technologies. Can we create synthesis between users of traditional enterprise data warehouses and those implementing federated knowledge graphs?
- Ben Gardener, Solution Architect – Knowledge Management, AstraZeneca
- Andrea Splendiani, Director of Data Strategy, Novartis
- Eric Little, CEO, LeapAnalysis
More speakers to be announced. Keep an eye on our website for more details!
The Benefits of Attending:
- Learn how biopharma and academic leaders have led FAIR implementation efforts to govern data across the R&D value chain
- Hear how strong senior level support has driven FAIR interoperability and data actionability through top-down management strategies
- Gather intelligence from off-the-beaten-path presentations and learn of the opportunities created for their respective organisations through FAIR programmes
- Understand the challenges of change management at the enterprise-level, considering the integration of broader IT technologies
This series is brought to you with the support of our sponsors, CDD, ONTOFORCE and LeapAnalysis.
Speakers
Tom Plasterer, Director of Bioinformatics, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca
Martin Romacker, Senior Principal Scientist in Scientific Solution Delivery and Architecture, Roche
Andrea Splendiani, Director of Data Strategy, Novartis
Philippe Rocca-Serra, Group Coordinator and Associate Member of Faculty, University of Oxford e-Research Centre
Hans Constandt, President and Founder, ONTOFORCE
Dr. Isabella Feierberg, Associate Principal Scientist, AstraZeneca
Dr. Ellen L. Berg, Chief Scientific Officer, Translational Biology, Eurofins Discovery
Dr. Lawrence Callahan, Chemist, Office of Health Informatics, Global Substance Registration System/Office of Health Informatics, Office of Chief Scientist, FDA
Dr. Hande Küçük McGinty, Research Scientist, Collaborative Drug Discovery (CDD Inc.)
